- Stable business model as key supplier to pharma and healthcare industry
- Gerresheimer sustains growth path. Revenue guidance for 2020 in the mid single-digit percentage range and adjusted EBITDA margin of around 21% confirmed
- Refinancing of EUR 190m promissory loan maturing in November 2020 secured ahead of time
- First quarter level with prior year, as expected: revenues EUR 304m, adjusted EBITDA EUR 51m
PR Newswire
DÃœSSELDORF, Germany, April 9, 2020